Insight on Ophthalmic Drugs Global Market to 2028 | Featuring Bayer, Abbott ,Pfizer, Novartis
According to Stratistics MRC, the Global Ophthalmic Drugs market is accounted for $36.70 billion in 2020 and is expected to reach $70.49 billion by 2028 growing at a CAGR of 8.5% during the forecast period.
The market report “Ophthalmic Drugs Market by Types (Over-the-Counter Drugs and Prescription Drugs), Technologies (Drug Delivery, Gene Therapy, Biologics, Small Molecule, and Cell Therapy), Drug Variations (Generic Drugs and Branded Drugs), Indications (Glaucoma, Dry Eye, Cataract, Retinal Disorders, Uveitis, Eye Infection/Inflammation/Eye Allergy, Allergic Conjunctivitis, Age-Related Macular Degeneration (AMD), Diabetic Eye Disease, and Other Indications), Distribution Channels (Drug Stores, Hospital Pharmacies, Online Pharmacies, Eye Health Clinics, and Retail Pharmacies/Independent Pharmacies), Route of Administrations (Systemic, Local Ocular, Topical, Oral, and Parenteral), Dosage Forms (Solid Ophthalmic Drug Forms, Liquid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, and Semisolid Ophthalmic Drug Forms), Delivery Types (Eye Solutions, Capsules & Tablets, Eye Ointment, Gels, and Eye Drops), Therapeutic Classes (Anti-Inflammatory, Antibiotics, Anti-Allergy, Anti-Glaucoma Drugs, Anti-Angiogenic, Anti-Infective Drugs, Anti-Vascular Endothelial Growth Factor (VEGF) Agents, Retinal Drug, and Other Therapeutic Classes (Cyclosporine)), End Users (Specialty Clinics, Hospitals, and Pharmacy), and Region – Forecast to 2028”. The Ophthalmic Drugs market is growing at a CAGR of 8.5% by 2028, owing to rising occurrence of ophthalmic disorders such as cataract, glaucoma, and other common eye infections.
Browse the complete report with 468 data tables and 78+ figures here: https://www.strategymrc.com/report/ophthalmic-drugs-market
Based on therapeutic class, the anti-vascular endothelial growth factor (VEGF) agents segment is estimated to grow at highest CAGR segment during the study period.
On the basis of therapeutic class, the market is categorised into anti-inflammatory, antibiotics, anti-allergy, anti-glaucoma drugs, anti-angiogenic, anti-infective drugs, anti-vascular endothelial growth factor (VEGF) agents, retinal drug, and other therapeutic classes (cyclosporine). Anti-vascular endothelial growth factor (VEGF) agents segment is estimated to be the fastest growing market segment strongly driven by the significant number of clinical trials being conducted on novel molecules for anti-VEGF activity, sturdy commercial recitals of Lucentis (ranibizumab), Avastin (bevacizumab), and Macugen (pegaptanib), the presence of global market players with extensive product portfolio.
Based on type, the over-the-counter drugs segment is anticipated to grow faster during the forecast period.
On the basis of type, the market is divided into over-the-counter drugs and prescription drugs. Over-the-counter drugs segment is projected to grow faster during the forecast period due to the large number of glaucoma patients, a substantial increase in generic perforation of ophthalmic drugs, the ease of use of OTC commodities to augment patient admittance, and loss of patent exclusivities of significant drugs.
We offer a 15% customization to be added within the report at no extra cost. To know more post your query here:
By geography, North America is expected to dominate the market
On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. North America is experiencing a dominant position in the market, owing to high consumer consciousness, growing numeral of patient population anguish from ocular diseases, the presence of outstanding healthcare infrastructure, high market saturation, increasing the incidence of eye diseases, and critical players’ existence.
The key players in this market are Bayer AG, Abbott Healthcare, Merck & Co., Pfizer, Inc., Novartis AG, Valeant Pharmaceuticals, Inc., Johnson & Johnson, Allergan Plc, Santen Pharmaceutical Co. Ltd., Genentech, Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Carl-Zeiss AG, and Hoya Corporation.
About Stratistics Market Research Consulting
Stratistics Market Research is a business research firm offering market reports across the industries. Our advanced techniques and tools in identifying the market trends helps in shaping today’s business landscape. Our syndicate and custom reports specialize in identifying new market opportunities. Our team of consultants help you to formulate a confident business strategy by providing competitive advantage. Our research services cover Market Entry Strategy, Strategic Benchmarking and Competitive Landscaping.
We have a core research team with analysts across the industry verticals to serve our varied customers such as technology suppliers, manufacturers, distributors, end-users, consulting companies, investment firms and research institutes.
Company Name: Stratistics Market Research Consulting
Contact Person: Kumar
Email: Send Email